학술논문
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer
Document Type
Article
Author
Source
In European Journal of Cancer January 2023 178:70-81
Subject
Language
ISSN
0959-8049